Other EGFR-positive Pediatric Solid Tumors Deemed Eligible by the Investigator Clinical Trials in Guangzhou, Guangdong

Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors